Publications by authors named "Ben Zhen Huang"

The field of platinum chemistry is ubiquitous in the research of anticancer drugs and new OLED materials. Within the vast library of existing compounds, the majority of work focuses on complexes in the +2 and +4 oxidation states, with comparatively few examples of Pt complexes reported without bridging ligands. Pt complexes with metal-metal bonding can be made by mild oxidation of Pt complexes having bis(phenylpyridine) ligands.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted antineoplastic immunotherapies face challenges like resistance due to the absence of specific targets or loss of antigens, limiting their effectiveness in treating tumors.
  • Researchers developed an oncolytic rhabdovirus, VSVΔ51, designed to express a truncated version of the HER2 antigen, which allows for effective targeting of tumors using the antibody-drug conjugate trastuzumab emtansine.
  • The study also combines VSVΔ51-HER2T with a vaccinia virus for a dual-virus treatment approach, showing strong potential for curative effects in living models, suggesting a promising method for improving the tumor microenvironment and enhancing treatment options.
View Article and Find Full Text PDF

The recent SARS-CoV-2 and mpox outbreaks have highlighted the need to expand our arsenal of broad-spectrum antiviral agents for future pandemic preparedness. Host-directed antivirals are an important tool to accomplish this as they typically offer protection against a broader range of viruses than direct-acting antivirals and have a lower susceptibility to viral mutations that cause drug resistance. In this study, we investigate the exchange protein activated by cAMP (EPAC) as a target for broad-spectrum antiviral therapy.

View Article and Find Full Text PDF

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer mortality worldwide, highlighting an urgent need for new therapeutic options and combination strategies for patients. The orchestration of potent T cell responses against human cancers is necessary for effective antitumour immunity. However, regression of a limited number of cancers has been induced by immune checkpoint inhibitors, T cell engagers (TCEs) and/or oncolytic viruses.

View Article and Find Full Text PDF